Chembio Diagnostics to Present at Three Conferences in January 2014
MEDFORD, N.Y., Jan. 9, 2014 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.
(Nasdaq:CEMI) a leader in point-of-care ("POC") diagnostic tests for
infectious diseases, announced today that Lawrence A. Siebert, Chief Executive
Officer, will present at three investor conferences next week. These
presentations will provide an overview of the company's products and programs
as well as anticipated milestones for 2014. Details regarding these events are
The Sidoti & Company Semi-Annual Micro-Cap Conference will take place on
Monday, January 13, 2014 at The Grand Hyatt Hotel, New York City, NY. The
conference will bring together institutional money managers and management
teams focused on the sub-200 million market cap sector. At least 70 companies
will tell their stories. Sidoti's stated criteria is to present "companies
that have sound fundamentals and intriguing stories, show fast growth and
profitability, or otherwise hold great promise, yet are largely unknown to
investors". Mr. Siebert will present at 9:20am ET. This conference is by
invitation only. For more information on the conference, please call or email
Lynn Orenstein at 212-453-7031 or firstname.lastname@example.org.
Biotech Showcase will take place from Monday, January 13 to Wednesday, January
15, 2014 at the Parc 55 Wyndham Hotel in San Francisco, CA. Biotech Showcase
is an investor and partnering conference devoted to providing private and
public life sciences companies with an opportunity to present to, and meet
with, investors and pharmaceutical executives in one place during the course
of one of the industry's largest annual healthcare investor conferences.
Registration information for Biotech Showcase can be found at
http://www.ebdgroup.com/bts/index.php. Mr. Siebert will present at 10:00am PT
on Tuesday, January 14 in the Mission II Room with a breakout session
immediately following. The Chembio presentation webcast will be available for
public access via the Investor Relations section of the Chembio corporate
website, www.chembio.com or at http://www.media-server.com/m/p/ekxfr29d where
it will be archived for 90 days.
OneMedForum will be held from Monday, January 13 to Wednesday, January 15,
2014 at The Westin San Francisco Market Street in San Francisco, CA. The
Seventh Annual OneMedForum will focus on the new financing strategies made
possible by the JOBS Act. OneMedForum's intent is that the conference "will
focus on the areas of greatest investment opportunity in therapeutics,
devices, diagnostics and health information and will also showcase the most
promising microcap public companies and high growth private (pre-IPO)
companies". Mr. Siebert will present at 2:00pm PT on Tuesday, January 14.
Registration information for OneMedForum can be found at
To schedule a meeting with Chembio management at any of these conferences,
please contact Stephanie Diaz at 415-675-7401 or email@example.com.
About Chembio Diagnostics
Chembio Diagnostics, Inc. develops, manufactures, licenses and markets
proprietary rapid diagnostic tests in the growing $10 billion point-of-care
testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests
are marketed in the U.S. by Alere, Inc. Chembio markets its HIV STAT-PAK® line
of rapid HIV tests internationally to government and donor-funded programs
directly and through distributors. Chembio has developed a patented
point-of-care test platform technology, the Dual Path Platform (DPP®)
technology, which has significant advantages over lateral-flow technologies.
This technology is providing Chembio with a significant pipeline of business
opportunities for the development and manufacture of new products based on
DPP®. Headquartered in Medford, NY, with approximately 200 employees, Chembio
is licensed by the U.S. Food and Drug Administration (FDA) as well as the U.S.
Department of Agriculture (USDA), and is certified for the global market under
the International Standards Organization (ISO) directive 13.485. For more
information, please visit: www.chembio.com.
Statements contained herein that are not historical facts may be
forward-looking statements within the meaning of the Securities Act of 1933,
as amended.Forward-looking statements include statements regarding the
intent, belief or current expectations of the Company and its management.Such
statements are estimates only, as the Company has not completed the
preparation of its financial statements for those periods, nor has its auditor
completed a review or audit of those results.Actual revenue may differ
materially from those anticipated in this press release.Such statements
reflect management's current views, are based on certain assumptions and
involve risks and uncertainties.Actual results, events, or performance may
differ materially from the above forward-looking statements due to a number of
important factors, and will be dependent upon a variety of factors, including,
but not limited to Chembio's ability to obtain additional financing, to obtain
regulatory approvals in a timely manner and the demand for Chembio's
products.Chembio undertakes no obligation to publicly update these
forward-looking statements to reflect events or circumstances that occur after
the date hereof or to reflect any change in Chembio's expectations with regard
to these forward-looking statements or the occurrence of unanticipated
events.Factors that may impact Chembio's success are more fully disclosed in
Chembio's most recent public filings with the U.S. Securities and Exchange
CONTACT: Chembio Diagnostics
(631) 924-1135, ext. 125
Vida Strategic Partners (investors)
Stephanie C. Diaz
Press spacebar to pause and continue. Press esc to stop.